SCHEMBL3593393

SCHEMBL3593393

CC1(C)Cc2cccc(N)c2NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.36
PPARG P37231 2/20 0.36
NCOR2 Q9Y618 2/20 0.36
PRNP P04156 1/20 0.36
ALDH1A1 P00352 4/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
PDK2 Q15119 3/20 0.34
PDK4 Q16654 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP19A1 P11511 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK3 Q15120 1/20 0.33
HTR5A P47898 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593391 0.79 RXFP1 (0.36) RXFP1PPARGNCOR2PRNPALDH1A1
SCHEMBL3593722 0.72 PDK2 (0.38) ALDH1A1KMT2AMEN1LMNAMAPT
SCHEMBL6220027 0.71 PDK2 (0.48) RXFP1PPARGNCOR2PRNPALDH1A1
SCHEMBL1654363 0.71 AHR (0.61) PDK2PARP1CD44AHR
SCHEMBL30100699 0.71 PDK2 (0.48) RXFP1PPARGNCOR2PRNPALDH1A1
SCHEMBL3593739 0.69 NPC1 (0.50) ALDH1A1KMT2AKDM4EMEN1LMNA
SCHEMBL10587563 0.69 TYMS (0.38) KMT2AMEN1MAPTPDK2PDK4
SCHEMBL3587267 0.69 BRD4 (0.54) KMT2AMEN1HPGDHTR5APARP1
SCHEMBL3639277 0.68 CA12 (0.37) ALDH1A1KMT2AKDM4EMEN1LMNA
SCHEMBL14550569 0.68 ACHE (0.40) ALDH1A1HTR5ACD44AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 RXFP1 432/4885PPARG 2100/4885NCOR2 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.